- Home
- HLF vs PRAX Comparison
HLF vs PRAX Comparison
Compare HLF & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLF
- PRAX
- Stock Information
- Founded
- HLF 1980
- PRAX 2015
- Country
- HLF United States
- PRAX United States
- Employees
- HLF N/A
- PRAX N/A
- Industry
- HLF Other Pharmaceuticals
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- HLF Health Care
- PRAX Health Care
- Exchange
- HLF Nasdaq
- PRAX Nasdaq
- Market Cap
- HLF 583.2M
- PRAX 599.7M
- IPO Year
- HLF N/A
- PRAX 2020
- Fundamental
- Price
- HLF $6.91
- PRAX $38.46
- Analyst Decision
- HLF Strong Buy
- PRAX Strong Buy
- Analyst Count
- HLF 4
- PRAX 10
- Target Price
- HLF $11.50
- PRAX $116.50
- AVG Volume (30 Days)
- HLF 2.3M
- PRAX 461.1K
- Earning Date
- HLF 04-30-2025
- PRAX 05-02-2025
- Dividend Yield
- HLF N/A
- PRAX N/A
- EPS Growth
- HLF 100.43
- PRAX N/A
- EPS
- HLF 2.74
- PRAX N/A
- Revenue
- HLF $4,950,500,000.00
- PRAX $8,122,000.00
- Revenue This Year
- HLF N/A
- PRAX N/A
- Revenue Next Year
- HLF $3.95
- PRAX $789.73
- P/E Ratio
- HLF $2.55
- PRAX N/A
- Revenue Growth
- HLF N/A
- PRAX 270.02
- 52 Week Low
- HLF $5.04
- PRAX $26.70
- 52 Week High
- HLF $12.79
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- HLF 48.47
- PRAX 54.88
- Support Level
- HLF $6.59
- PRAX $34.89
- Resistance Level
- HLF $7.53
- PRAX $40.89
- Average True Range (ATR)
- HLF 0.46
- PRAX 2.30
- MACD
- HLF 0.06
- PRAX 0.74
- Stochastic Oscillator
- HLF 52.78
- PRAX 68.87
About HLF Herbalife Ltd.
Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management; targeted nutrition; Energy, Sports, and Fitness; Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Mexico, South and Central America, EMEA, Asia-Pacific, and China.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.